GlassScriptPhysician profile
Kevin Witt
NPI 1023076510
$281.55
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2021: $50.00.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $90.18 | 2019 | |
| Novo Nordisk INC | $69.89 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $40.24 | 2019 | |
| Amarin Pharma, INC. | $16.48 | 2019 | |
| Glaxosmithkline, LLC. | $14.21 | 2019 | |
| Antares Pharma, INC. | $13.57 | 2019 | |
| Ethicon US, LLC | $13.46 | 2019 | |
| Sanofi Pasteur INC. | $12.20 | 2019 | |
| Lilly USA, LLC | $11.32 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Witt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.